ICSS INTERNATIONAL CELL SURGICAL SOCIETY **Annual Report** 2017-2018

About ICSS

Mission Statement

Conducting and supporting education, research and the advancement of knowledge and public awareness of stem cell therapy and regenerative medicine.






The International Cell Surgical Society (ICSS) is a 501(c)3 non-profit organization founded to promote autologous stem cell therapy and the advancement of regenerative medicine.

ICSS The serves the regenerative medical community through establishing standards for the practice of cell-based medicine, providing improved oversight by an HHS approved institutional review board bio-ethics committee, comprised of world renowned scientists and professionals, supporting ongoing vital physician education, and supporting basic research.



The ICSS supports the vision of regenerative medical therapies based on our own bodies' healing abilities should be available to everyone who might benefit from such treatments.

Promoting Education



The 5th Annual Cell Surgical Conference

The ICSS hosted the 5th International Cell Surgical Conference at the Beverly Hilton Hotel. This conference brought together some of the world's leaders in stem cell and regenerative medical reseach. Both clinicians and scientists spent two days discussing the latest developments in cellular therapies, which included but were not limited to adipose derived stem cells, bone marrow derived stem cells, platelet rich plasma, exosomes, growth factors and more.



250+ Attendees

The conference attendance grew by over 20% year over year.



Over 20 Speakers



Over 15 Countries Represented

USA, Canada, Germany, Japan, China, South Korea, UAE, India, etc.



3 Days, 8 CMES



IRB Accomplishments

The ICSS IRB is committed to providing peer review of proposed studies of investigational medical therapies based upon appropriate clinical translation, good patient care and safety. The purpose of this IRB is to evaluate and access potential risk to human subjects.

The mission of the ICSS IRB is patient safety: to maintain an effective Human Research Protection Program to protect the rights and welfare of human participants in research reviewed under the auspices of our IRBs. While discussion of study methodology is allowed, final determination of approval must be based upon entirely upon risk and patient safety.

2018 Protocols

The IRB approved 16 protocols in 2018, adding 4 new protocls from 2017

IRB Members

The IRB consists of 7 memebrs with medicine, law and more

IRB Meetings

The IRB conducted 7 meetings throughout 2018

Clinical Review The IRB reviewed and monitored over 2,000 clincial cases for adverse and serious adverse events

Charity and ReserachFunding

ICSS seeks to give back to the scientific and medical community In 2018, ICSS funded the following:

-5 full cell therapy procedures

-Equipment for over 25 cell therapy procedures -Laboratory research on traumatic brain injury -Laboratory research on chronic traumatic

This funding and subsequent research resulted in the peer reviewed publication of 4 scientific articles in the past year.

Financials At A Glance

encephalopathy

Operations: \$46,312.50 Donations:\$30,856.11 Travel & Meetings: \$18,012.19 Cell Surgical Conference: \$255,015.00 Net Income: (\$124,138.60)